Oral Chemotherapy Versus Supportive Therapy In The Treatment Of Unresectable Hepatocellular Carcinoma
Status:
Unknown status
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
Background Hepatocellular carcinoma, a malignant tumour of liver is one of the most common
cancers worldwide. All India Institute Of Medical Sciences (AIIMS) being a tertiary care
hospital receives about two to three cases of Hepatocellular carcinoma (HCC) each day in the
investigators Gastroenterology out patient department. Most of these patients present late
when the disease is already advanced and no curative therapies can be offered. At this stage,
palliative therapy forms the mainstay of treatment. This includes transarterial
chemoembolization (TACE) or Oral chemotherapy. Many patients also have involvement of
branches of portal vein, which further limit therapeutic options. According to Barcelona
Clinic Liver Cancer (BCLC) staging of liver cancer, involvement of portal vein precludes any
standard form of therapy. These patients have been recommended for experimental therapies.
Various forms of chemotherapy have been tried this group of patients. HCC is a vascular
tumour and thalidomide is an anti-angiogenic drug and inhibits vascularity and has been used
in the treatment of HCC. Capecitabine is a novel drug, which gives continuous delivery of
5-FU and has been used in patients with HCC and has been found to be safe.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
All India Institute of Medical Sciences, New Delhi